Q1 2026 MiMedx Group Inc Earnings Call Transcript

Apr 29, 2026 / 08:30 PM GMT

Release Date Price: $3.09 (-9.26%)

Transcript 8-K10-Q

Key Points

Positve

MiMedx Group Inc (MDXG) reported a 13% growth in its surgical business for Q1 2026, showcasing strong performance in this segment.
The company ended the quarter with a robust cash position of $142 million, providing financial stability.
MiMedx Group Inc (MDXG) completed enrollment in its EpiEffect randomized control trial, indicating progress in its research initiatives.
The company launched new surgical products, including AmnioFix Thyroid Shields, contributing to its diversified product portfolio.
MiMedx Group Inc (MDXG) has initiated a $100 million share repurchase program, reflecting confidence in its financial health and commitment to shareholder value.

Negative

The wound care business experienced a significant 60% decline in sales year-over-year, heavily impacted by changes in Medicare reimbursement policies.
The company reported an adjusted EBITDA loss of $12 million for Q1 2026, indicating financial challenges.
MiMedx Group Inc (MDXG) faced disruptions due to the new Medicare reimbursement framework, leading to market contraction and operational challenges.
The implementation of the Wiser Model in certain states resulted in significant delays and inefficiencies in claims processing.
The company had to undertake a restructuring and cost reduction initiative, including a 15% workforce reduction, to address financial pressures.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MDXG.OQ - MiMedx Group Inc
Q1 2026 MiMedx Group Inc Earnings Call
Apr 29, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon, and thank you for standing by. Welcome to the MyMedics First Quarter 2026 Operating and Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Mr. Matt Notariani, Head of Investor Relations for MyMedics.

Thank you.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and good afternoon, everyone.

Welcome to the

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.